|
|
|
WST Forecast
Recent WST Price |
|
WST Forecast Price |
$360.43 |
+12.04% |
$403.83 |
As of 2024-04-29
Recent WST Analyst Ratings Breakdown |
|
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
Strong buy ratings: |
5 |
5 |
5 |
4 |
Buy ratings: |
0 |
0 |
0 |
0 |
Hold ratings: |
2 |
2 |
2 |
3 |
Sell ratings: |
0 |
0 |
0 |
0 |
Strong sell ratings: |
0 |
0 |
0 |
0 |
Average rating: |
1.57 |
1.57 |
1.57 |
1.86 |
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.
For the West Pharmaceutical Services, Inc. forecast (traded under symbol WST) for one year forward price target at the top of this page, we have presented the average WST forecast for forward target price across the 6 analysts covering WST, as reported in
data provided by Zacks Investment Research via Quandl.com.
Meanwhile, note that the
median WST forecast price target (median being the middle where half of analysts had a higher WST forecast and half had a lower WST forecast, which is a different metric than the average or mean) was $400.0 as of 2024-04-29, while the
highest WST forecast in the analyst group was $470.0, and the lowest WST forecast in the analyst group was
$355.0, with a standard deviation of $39.977. Get the latest Zacks research report on WST — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
|
|
|
Buy (3.43 out of 4)
56th percentile
|
PARTNER NEWS:Thu, Apr 25, 8:31 AM, Zacks
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
Thu, Apr 25, 5:10 AM, Zacks
West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates West Pharmaceutical (WST) delivered earnings and revenue surprises of 20.93% and 3.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
|
|